A B S T R A C T
In March this year, the American Statistical Association (ASA) posted a statement on the correct use of P-values, in response to a growing concern that the P-value is commonly misused and misinterpreted. We aim to translate these warnings given by the ASA into a language more easily understood by clinicians and researchers without a deep background in statistics. Moreover, we intend to illustrate the limitations of P-values, even when used and interpreted correctly, and bring more attention to the clinical relevance of study findings using two recently reported studies as examples. We argue that P-values are often misinterpreted. A common mistake is saying that P < 0.05 means that the null hypothesis is false, and P !0.05 means that the null hypothesis is true. The correct interpretation of a P-value of 0.05 is that if the null hypothesis were indeed true, a similar or more extreme result would occur 5% of the times upon repeating the study in a similar sample. In other words, the P-value informs about the likelihood of the data given the null hypothesis and not the other way around. A possible alternative related to the P-value is the confidence interval (CI). It provides more information on the magnitude of an effect and the imprecision with which that effect was estimated. However, there is no magic bullet to replace P-values and stop erroneous interpretation of scientific results. Scientists and readers alike should make themselves familiar with the correct, nuanced interpretation of statistical tests, P-values and CIs.
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I N T R O D U C T I O N
The groundwork for hypothesis testing and statistical significance testing dates from the seminal works by Fisher, Neyman and Pierson in the 1920s and 1930s. Unfortunately, their work has been misunderstood and misused too often for nearly a century, despite decades of warnings issued by statisticians. Last March, the American Statistical Association (ASA) posted a statement on the correct use of P-values [1] . Their rationale: a growing concern and body of evidence that 'while the P-value can be a useful statistical measure, it is commonly misused and misinterpreted.' This statement from the ASA once again proves that even though this topic has been discussed over and over, it is still relevant and accompanied by many misconceptions in science in general. In our experience, the field of kidney disease research is unfortunately no different. In the present article, we aim to translate the warnings given by the ASA into a language more easily interpreted by clinicians and researchers without a deep background in statistics. Moreover, we intend to illustrate the limitations of P-values, even when used and interpreted correctly, and bring more attention to the clinical relevance of study findings. We do this with two examples: a study by Bainey et al. [2] that did not reach statistical significance, but had a large effect size, and the Study of Heart and Renal Protection (SHARP) study, which showed a statistical significant effect, but had a modest effect size [3] .
E X A M P L E S T U D I E S
Stopping or continuing renin-angiotension inhibition to prevent contrast-induced nephropathy Recently, Bainey et al. published the results of a randomized controlled trial investigating the potential protective effect of withholding angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in patients who had chronic renal insufficiency and who were scheduled to undergo a cardiac catheterization including contrast enhanced coronary angiography [2] . The authors hypothesized that due to their mechanism of action, ACEi and ARBs may have detrimental Nephrol Dial Transplant (2017) 32: ii6-ii12 doi: 10.1093/ndt/gfw385 Advance Access publication 7 January 2017
effects on the kidney if combined with intravenous iodine contrast. Therefore, withholding these drugs around the time of a cardiac catheterization may help reduce the risk of contrastinduced nephropathy (CIN) in patients with renal insufficiency (see clinicaltrials.gov: NCT00317252). Table 1 shows the outcomes of the study, i.e. withholding ACEi/ARBs treatment prior to cardiac catheterization reduced the occurrence of CIN by 41% (P ¼ 0.16). Based on these results, the authors concluded that withholding ACEi/ARBs prior to cardiac catheterization resulted in a 'non-significant reduction in contrast induced acute kidney injury and a significant reduction in postprocedural rise of creatinine.' They recommend that '[withholding ACEi/ARB treatment] could be considered when referring a patient for angiography. However, larger adequately powered clinical trials are required to prove definitive benefits in reducing contrast-induced AKI.' In other words, they feel more research is needed and are hesitant to give definitive advice.
The use of lipid-lowering drugs in patients with chronic kidney disease
In 2011 the SHARP study group presented the results of a randomized controlled trial investigating the potential protective effect of using simvastatin plus ezetimibe compared with placebo in patients with chronic kidney disease (CKD). In patients with a glomerular filtration rate >60 mL/min/1.73 m 2 , we know that statin therapy reduces vascular events; the authors questioned whether lipid-lowering therapy remains effective as renal impairment progresses (see clinicaltrials.gov: NCT00125593). After a median follow-up of 4.9 years, the occurrence of any major atherosclerotic event was reduced by 17% in the lipid-lowering drugs group compared with the placebo group (P ¼ 0.0021). Based on these results, the authors concluded that 'lowering LDL cholesterol with the combination of simvastatin plus ezetimibe safely reduces the risk of major atherosclerotic events in a wide range of patients with CKD.' Furthermore, they suggested that 'widespread use of LDLcholesterol-lowering therapy in patients with CKD would result in a worthwhile reduction in cardiovascular disease complications.'
What do these results mean for clinical practice?
A question that is often voiced after discussing such research papers: How must we interpret the results? Are the recommendations based on the magnitude of effect of the intervention or the P-value of the effect? Is a P-value >0.05 a chance finding? Should we disregard the results, postpone judgement and continue to practice as if these data were never published if the P-value is greater than 0.05, and take any result for truth if the P-value is lower than 0.05? In order to answer these questions, we need to dive deeper into the meaning of P-values and effect estimation.
H Y P O T H E S I S T E S T I N G A N D T H E P -V A L U E

The goal of hypothesis testing
In medical science, we aim to uncover the causes of disease, evaluate diagnostic procedures, predict prognosis and identify which interventions prevent poor health outcome. However, Popper [4] argued that it is not possible to provide definitive proof of a theory through experiments. We may simply have not found the evidence to disregard that theory yet, since we can never be sure that the next trial will give the same result. Instead, we must try to formulate competing theories and collect evidence to reject these. If we then find a single example that contradicts the competing theory, we know this theory to be false, or at least incomplete. The more a theory stands up to attempts to reject it, the more confident we can be that it is true. Therefore, to gain confidence that a theory is true, we must subject it to rigorous attempts to show it is false, and we must demonstrate that an opposing theory is false as well. In our first example, we want to know if withholding ACEi/ARBs reduces the incidence of CIN in patients with renal insufficiency undergoing cardiac catheterization. To prove that this is the case, we need to find sufficient evidence to reject the opposing theory that withholding ACEi/ARBs does not influence the incidence of CIN. Likewise, in the second example we need to find sufficient evidence to reject the hypothesis that there is indeed no difference for cardiovascular risk between patients with CKD who do and patients who do not receive lipid-lowering drugs. This process of 'falsification' is the foundation for many scientific methods.
The null hypothesis and alternative hypothesis
If withholding ACEi/ARBs reduces the incidence of CIN patients with renal insufficiency undergoing cardiac catheterization, and if lipid-lowering drugs prevent the occurrence of cardiovascular events in patients with CKD, we would expect a difference in the incidence of the respective outcomes between the experimental groups in either study. From this expectation, we can formulate the opposing hypothesis that there will be no difference in the incidence of the outcome in the respective studies. By falsifying this opposing hypothesis, we can strengthen the evidence for the hypothesis in which we are interested. The latter, opposing hypothesis is referred to as the 'null hypothesis'. In more formal terms, the hypotheses for the study by Bainey et al. were:
• Null hypothesis-H 0 : the incidence of CIN 'is not different' between a group of patients who discontinue ACEi/ARB therapy and a group of patients who continue ACEi/ARB therapy when undergoing cardiac catheterization. S t a t i s t i c a l s i g n i f i c a n c e v e r s u s c l i n i c a l r e l e v a n c e ii7
• Alternative hypothesis-H a : the incidence of CIN 'is different' in the group of patients who discontinue ACEi/ARB therapy compared with the group of patients who continued ACEI/ARB therapy when undergoing cardiac catheterization.
Similarly, the hypotheses for the SHARP study were:
• Null hypothesis-H 0 : the incidence of major atherosclerotic events 'is not different' between a group of patients who use lipid-lowering drugs and a group of patients who use placebo.
• Alternative hypothesis-H a : the incidence of major atherosclerotic events 'is different' in the group of patients who use lipid-lowering drugs compared with the group of patients who use placebo.
Even though we expect the incidence of CIN to be lower when we withhold ACEi/ARB treatment, it may also turn out to be higher. Likewise, the risk of atherosclerotic events could very well be higher in patients treated with lipid-lowering drugs. This is why the alternative hypothesis is formulated as 'is different' and not as 'is lower'. This also means that we should perform a 'two-tailed test' of the null hypothesis. If we are not interested in the direction of the treatment effect, for example, if we expect no-one to be cured in the placebo group, and therefore, the direction of the effect can only be positive, we could opt for a 'one-tailed' test. The difference between one-tailed and two-tailed tests is that the criterion to accept statistical significance is more strict when we perform a 'two-tailed' test. By convention, two-tailed tests are generally used in medical science. The origins of this convention are detailed in an excellent editorial published recently [5] .
Type I and type II error
We can never be certain that we are right in either accepting or falsifying a hypothesis. We run the risk of making two kinds of errors. The null hypothesis can be rejected falsely, known as a type I error. For example, when we conclude that treating patients suffering from CKD with lipid-lowering drugs reduces cardiovascular risk when it does not in reality. The second error is when we fail to reject the null hypothesis when there is in fact a difference between the groups, also called type II error. For example, when we conclude that the intervention of withholding ACEi/ARB treatment during coronary catheterization does not reduce incidence of CIN in patients with renal insufficiency when in fact it does. These errors cannot be fully eliminated, but we can lower the chance of making such errors. By choosing a lower threshold for statistical significance we can reduce the type I error rate, and by increasing the sample size or taking more precise measurements of the outcome variable we can reduce the type II error rate.
Obtaining and interpreting a P-value
After data have been collected, we can summarize the occurrence of the outcome in a table, see Tables 1 and 2 . From these tables, we can calculate P-values with a chi-squared or Fisher exact test. As the procedures to do so are readily available in statistical software, we will not go into detail about the calculations. The P-value for the difference in the frequency of CIN between the treatment groups was 0.16 (Table 1 ). This roughly means that assuming that the treatment had no effect, we would observe a similar or larger difference between the treatment group and control group in 16% of similar, future studies. The P-value for the difference in the frequency of atherosclerotic events between the treatment group and placebo group was 0.0021 (Table 2 ). This means that assuming that the treatment had no effect, we would observe a similar or larger difference between the treatment and placebo group in 0.21% of similar, future studies. Obviously, if the P-value is very small, we would doubt whether the null hypothesis is compatible with the data we collected. We may then reject the null hypothesis in favour of the alternative hypothesis. Note, that even though the P-value may be very small, we cannot say with certainty that the alternative hypothesis must be true. A more extreme result may be unlikely in light of the data, but not impossible. Moreover, the P-value by itself gives no indication of the magnitude of the difference between the groups [1] . If the sample size is very large or a measurement was performed very precisely, we may be able to find a statistically significant difference even if the difference itself is not 'clinically relevant'. The SHARP study included 9270 patients whereas the study of Bainey et al. included only 208 patients; therefore, with similar effect sizes, we can expect to find much smaller P-values in the SHARP study based on its sample size alone.
E F F E C T E S T I M A T I O N
The goal of effect estimation Essentially, the primary aim of a hypothesis test is to answer a research question with either yes or no. Effect estimation on the other hand aims to provide a quantitative assessment of the difference between two (or more) study groups and provide a range of likely values for that difference. The measure of effect in our examples is the risk ratio. From Table 1 , we can see that the risk of CIN was 10.9% in patients Any major atherosclerotic event was defined as non-fatal myocardial infarction or any cardiac death, any stroke or any arterial revascularization excluding dialysis access procedures.
who discontinued ACEi/ARB treatment compared with 18.4% in patients who continued ACEi/ARB use, resulting in a risk ratio of 0.59 (¼10.9%/18.4%). This can be interpreted as a 41% reduction in the occurrence of CIN in patients who discontinued ACEi/ARB treatment compared with patients who did continue ACEi/ARB therapy during cardiac catheterization. Likewise, the risk of atherosclerotic events was 13.4% in the place group and 11.3% in the lipid-lowering drug group resulting in a risk ratio of 0.83 (¼11.3%/13.4%), which can be interpreted as a 17% reduction in the occurrence of major atherosclerotic events.
Obtaining and interpreting a CI
Effect estimates such as the risk ratio and related measures (e.g. risk difference, odds ratio or incidence ratio) are often presented with a confidence interval (CI). The CI provides a range of possible values for the effect. It can be obtained by estimating the precision of the estimate using the 'standard error' of the effect. The standard error can be determined from the variability in the data and the sample size. Similar to the hypothesis test described above, statistical software to obtain standard errors and CIs is readily available and we will not go into the detail about the calculations. In the example of Bainey et al., the 95% CI around the risk ratio ranged from 0.31 to 1.19. A 95% CI roughly means that if we repeat the experiment with similar samples, and if we compute the CIs from each sample, 95% of the CIs will include the true, unknown risk ratio value.
P-value function and the CI width
The CI and the P-value are mathematically related. In order to create a CI, we must choose a threshold for the confidence level, usually specified as a. An a of 0.10 corresponds to statistical significance at the P ¼ 0.10 level and confidence level of 90%, i.e. 1 À a. In our example, we chose an a of 0.05, as this is used by convention. However, we may choose a different a if we wish. In fact we could take a range of a-values and plot these in a 'P-value function' [6] . Figure 1 shows the P-value function for both our examples. The left y-axis shows the P-value and the right y-axis the confidence level. From both y-axes in Figure 1 , we can appreciate the relation between the P-value and the confidence level: they are mirror images. The 95% CI means that when we repeat a study many times in similar samples, the observed CIs will cover the true risk ratio 95% of the times. Conversely, a P-value of 0.05 means that if the null hypothesis were true and we were to repeat a study, a similar or more extreme risk ratio would be observed only 5% of the times.
The black line in Figure 1 shows the P-value function for hypothesized risk ratio determined from study by Bainey et al. [2] ; the grey line signifies the risk ratio for the SHARP study [3] . The peaks of the curves correspond to the point estimates for the risk ratios, being 0.59 and 0.83 in the study by Bainey and in the SHARP study, respectively. If we perform a statistical test and obtain a P-value, that P-value corresponds to the y-coordinate of the P-value function at a risk ratio of 1, indicated by a dashed line in the figure. For the study by Bainey, the P-value function intersects a risk ratio of 1 at 0.16, and for the SHARP study it intersects at a P-value of 0.002.
If we report a CI around the point estimate, we can obtain the corresponding confidence limits on the horizontal axis. For example, if we set the confidence level to 95%, which mirrors a two tailed P-value of 0.05 (i.e. a ¼ 0.05), we a get lower limit of 0.31 and an upper limit of 1.19 for the risk ratio observed in the study by Bainey, marked by the black arrows. Likewise, we get a lower limit of 0.74 and an upper limit of 0.94 for the SHARP study. Thus, the P-value function provides a summary of both the effect size and the precision with which the effect is estimated. From the P-value functions and the CIs, we can immediately see that the risk ratio obtained in the study by Bainey is lower compared with the risk ratio in the SHARP trial. However, the precision with which that risk ratio was estimated was smaller, as indicated by the wider P-value function and wider corresponding CI.
The benefits of using CIs become even more apparent if we consider the hypothetical P-value functions in Figure 2 . Here we plotted the P-value functions for a small effect (risk ratio ¼ 1.1, 95% CI: 1.0-1.21) that was estimated with high precision (the narrow P-value function). High precision can be achieved by taking a large sample size for example. In addition, we plotted a large effect (risk ratio ¼ 2.0, 95% CI: 0.95-4.21) that was estimated with low precision (the wide P-value function). Both functions intersect the risk ratio value of 1 at a P-value of 0.05. Therefore, based on the P-value alone, we may erroneously conclude that the effects that produced these P-values are similar. However, if we construct the corresponding CIs, we can clearly see a world of difference. The P-values for these estimates may be similar, but the effect size and therefore clinical relevance is clearly not. 
C O M M O N M I S C O N C E P T I O N S A N D M I S T A K E S
In this section, we highlighted some of the most common and, in our opinion, grievous mistakes in the use of P-values. For more elaborate discussion and explanations, see the work by Greenland et al. [7] and Goodman [8] .
The false dichotomy of P < 0.05, and '*' versus P !0.05 and non-significant Before the advent of commonly available statistical software, test statistics such as the chi-square statistic and T statistic had to be calculated manually. The resulting value was then compared with a printed table with P-values belonging to the value of the test statistic at varying degrees of freedom. To save space these tables were printed with arbitrary thresholds for P-values. Moreover, Fisher argued to 'set a low standard of significance at the 5 percent point.' Based on this magical threshold, and the work by Neyman and Pearson [8] , researchers often present the results of a statistical test as 'significant' or '*' by which they mean that a P-value less than 0.05 was noted and 'non-significant' (n.s.) when a P-value is greater than or equal to 0.05. While there is almost no difference between P ¼ 0.045 and P ¼ 0.055, they belong to two different worlds when we dichotomize the continuum of P-values.
As described in the section 'P-value function and the CI width', the P-value has little meaning by itself. It has nothing to do with the magnitude or the importance of an observed effect. 'Any effect, no matter how small in terms of clinical impact, can produce statistical significance if the sample size is large enough or measurement precision is high enough' [1] . For example, the SHARP study showed that using lipid-lowering therapy led to a
of the study) in order to prevent one major atherosclerosis event. Furthermore, the numbers needed to treat to prevent any of the separate outcomes are even bigger, 250 to prevent a single major coronary event, 100 to prevent one nonhaemorrhagic stroke and 67 to prevent a single revascularization. This means that a fairly large number of patients will have to suffer potential harm due to possible side effects and additional expenses for a single person to benefit. The balance of benefit and harm is determined by the magnitude of the effect rather than it being statistically significant. For example, the study by Bainey et al. did not find a statistically significant decrease in CIN incidence when withholding ACEi/ARBs treatment, but the number needed to treat to prevent one CIN occurrence was only 13 [¼1/(18.4 À 10.9)] patients. Hence, a clinically important difference may be missed if only 'not statistically significant' is reported without any mention of effect size. Please note that the 'number needed to treat', i.e. the inverse of the risk difference, and risk ratio are related. Both reflect the magnitude of the effect of an intervention (or exposure), and both are estimated with a degree of uncertainty that can be reflected by a CI.
Moreover, Fisher never intended the P-value of 0.05 to be used as a black and white interpretation of statistical significance. Instead, he felt that 'A scientific fact should be regarded as experimentally established only if a properly designed experiment rarely fails to give this level of significance' [8] . In other words, experiments that result in low P-values ought to be reproduced before we can really believe the results.
The P-value indicates the probability that the null hypothesis is true
The P-value does not tell us much about the null hypothesis itself. Instead, it reflects the chance of observed result occurring if the null hypothesis were true. To illustrate this, we will take a bird's eye view of the scientific evaluation of medical therapies. To do so, we imagine a universe where lipid lowering does not affect atherosclerosis, i.e. the risk ratio for atherosclerosis after lipid-lowering drug exposure is 1. In this universe we have 10 000 people, half of whom use lipid-lowering drugs. Researchers perform a series of 1000 studies to evaluate the use of lipid-lowering drugs, each time including 1000 people. The chance of atherosclerosis occurring was 10%. The results of our simulation are shown in Figure 3 . The mean observed risk ratio for the series of studies was 1.04, close to the true risk ratio of 1. However, in one of the studies, the researchers found a risk ratio of almost 2 was found, and the result was statistically significant. However, we, the creators of this simulated universe, know that there is no effect in reality. Thus the true meaning of the P-value and the misconception become apparent: the observed risk ratio of 2 is very unlikely given the null hypothesis, but not impossible, nor does it mean that the null hypothesis itself is false.
Multiple testing and selective reporting
Selective reporting is perhaps the most common error in scientific literature and one of the worst. The problem is we have highlighted that a P-value is related to a pre-specified hypothesis. For example, Bainey et al. detailed a plausible mechanism for the effect of ACEi/ARB therapy on CIN [2] . Likewise, at the time of the SHARP study, use of lipid-lowering drugs was already proven to be effective in patients without a preserved kidney function [3] . However, testing random multiple, not pre-specified hypotheses leads to erroneous chance findings. Consider the subgroup analyses performed in the SHARP study, for example [3] . In total, 15 extra comparisons are made between the treatment arms. In this case, the probability of observing at least one P-value smaller than 0.05 due to random sampling, or 'noise', alone is 54% [¼1 À (1 À 0.05) 15 ]. Indeed, the authors report P-values lower than 0.05. The lipid-lowering treatment seems to be stronger in patients with a high body mass index and people with a high serum cholesterol. Fortunately, the SHARP investigators have reported all subgroup analyses and not just the ones that reached statistical significance. Thus, we can take into account the possibility that some of these differences may be chance findings, for instance, with a formal adjustment for multiple testing [9] . However, if a researcher cherry-picks findings based on the P-value, by digging for and only reporting statistical significant results, correct interpretation of the hypothesis becomes impossible, as we cannot determine how many analyses were performed. The cherrypicking problem is aggravated by the fact that results that are not statistically significant are less likely to be reported, known as the 'file drawer problem'. Some authors have gone as far as claiming that most reported findings in medical literature are spurious as a consequence [10] . Others have shown that this claim itself may have been the result of a mis-specified model [11] . Nevertheless, selective and incomplete reporting is known to be an important problem in systematic reviews and metaanalysis of the medical scientific literature, resulting in biased effect estimates in meta-analyses [12] .
C O N C L U S I O N
In summary, hypothesis testing and falsification is the foundation for many scientific methods. By falsifying an opposing hypothesis, we strengthen the evidence for the hypothesis in which we are interested. This falsifying can be done with the aid of a statistical test. Such tests give a P-value: the probability that we would get an equal or more extreme result upon repeating the experiment 'if' the null hypothesis is in fact true. Even though a P-value can be very small, we cannot say with certainty that the alternative hypothesis is true. A more extreme result may be unlikely in light of the data, but not impossible. Furthermore, other competing hypotheses may take precedence over the alternative hypothesis. In addition, any effect can produce statistical significance if the sample size is large enough or measurement precision is high enough, even if the difference itself is not clinically relevant. To assess if the observed difference is clinically relevant, the effect should be estimated (e.g. a difference in means, a difference in frequencies, a ratio of risks, etc.). These effects should be presented with a CI, which provides a range of plausible values for the effect, summarizing both the effect size and the precision with which the effect is estimated.
With this article, we have tried to give physicians in nephrology a brief introductory guide into P-values and CIs. Therefore, we have simplified some aspects; for more detailed information on the use of P-values we refer to the paper of Greenland et al. [7] . In addition, we want to note that the hypotheses discussed in this article are only valid for superiority trials-trials where we want to show that an intervention is superior to the control. Noninferiority and equivalence trials need another approach [13] .
Back to our examples: How could we interpret these results? We need to evaluate the possible impact of the results. Bainey et al. found a 41% reduction of CIN incidence [2, 14] . From the CI, we can provide a likely (95%) range for the risk ratio between 0.30 and 1.19. Alternatively, the P-value indicates that if there is actually no difference, a similar or more extreme effect will be found in 16% of any repeated experiments. The number of patients needed to treat in order to prevent one CIN event is 13. Assuming that the study was properly conducted, we feel that the conclusion from Bailey et al. are overly cautious given the relatively low impact of discontinuing ACEi/ARBs for a week, the low number of patients needed to treat to prevent one CIN event, the potentially severe consequences of CIN and the rather large effect size. Note that this not a purely statistical argument, but it is based on the magnitude of effect of the intervention and its possible adverse consequences.
On the other hand, the SHARP study found a 17% reduction of atherosclerotic events occurrence with a likely 95% range of the risk ratio between 0.74 and 0.94, and a P-value that indicates that if there is no difference a similar of more extreme effect will be found in only 0.21% of the cases. Statistical significance has been reached in this study. However, 48 patients would need to be treated for 5 years in order to prevent one atherosclerotic event.
FIGURE 3: Plot of the observed P-value by the observed risk ratio for 1000 subsets of n ¼ 1000 patients from an original dataset that contained 10 000 patients. We set the risk ratio to 1 in the original data. Each circle corresponds to the risk ratio and P-value observed in a single subset. The vertical line indicates the mean observed risk ratio (¼1.04) for the samples. The horizontal dashed line is at the 0.05 significance level.
S t a t i s t i c a l s i g n i f i c a n c e v e r s u s c l i n i c a l r e l e v a n c e Finally, we would once again like to point out that there is no magic bullet to replace P-values and stop erroneous interpretation of scientific results. Some have argued to abolish Pvalues altogether [15] . However, we feel that that would be throwing out the baby with the bath water. Instead, we hope that this text helps, and educates the reader in correctly interpreting the results of statistical tests in their own work and in that of others. 
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